Maynard Um
-
-
-
-
-
-
-
Natera partners with Angiex to monitor cancer drug trial with ctDNA test
-
-
-
-
-
-
-
Natera's Signatera test linked to survival benefit in colon cancer
-
-
-
-
-
-
-
RBC Capital Starts Natera (NTRA) at Outperform
-
-
-
-
-
-
-
Natera's fetal genetic testing trial enrolls over 2,000 patients
-
-
-
-
-
-
-
Court awards Natera 30% ongoing royalty in patent dispute
-
-
-
-
-
-
-
Piper Sandler Highlights 'A Number of Growth Opportunities' at Natera (NTRA)
-
-
-
-
-
-
-
Natera reports preliminary 2025 revenue growth of 35% to $2.3 billion
-
470,321 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


